Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Drug Allergy
•
Primary Care
Do you believe that pretreatment with montelukast or other LTRAs can reduce the risk of urticaria or angioedema with NSAIDS?
Related Questions
What medications would you have a patient avoid with an IgE mediated reaction to cyclobenzaprine?
Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?
Does food sensitivity testing for IgG subclasses help guide your management of food allergy?
Are you using any AI models to de-label penicillin allergy?
Is it necessary to prescribe a steroid taper after two weeks of high-dose prednisone (60 mg daily)?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
What treatment approach do you suggests for a patient with nasal polyp disease and asthma who was improved on dupilumab, but over last 2 years has begun to have increased nasal symptoms and rising eosinophil counts?
Is omalizumab an option for a patient needing a specific antibiotic with an IgE-mediated reaction who continues to have reactions during a desensitization?
Would you ever use dupilumab for atopic dermatitis in a patient who also has EGPA?
Do you use asthma or EoE dosing if initiating dupilumab in a patient who meets criteria for treatment for both disorders?
